Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts
The MRF is the largest independent organization dedicated to melanoma research, education of patients and their caregivers and advocacy on both the federal and state-level. The “Ask the Expert” Managing Melanoma series is aimed at increasing awareness and engagement in the melanoma community and will feature leading dermatologists and melanoma experts.
The Facebook Live webinars are accessible to the public and will take place on the MRF Facebook page with the following industry leaders:
April 6, 2021@ 3 p.m. E.T.: Abel Jarrell, M.D., dermatology/dermatopathology, Melanoma Patient Journey
April 13, 2021@ 4 p.m. E.T.: Brent Moody, M.D., Mohs surgeon, Familial Genetics vs. Tumor Genetics
April 20, 2021@ 4 p.m. E.T.: Shannon Trotter, D.O., dermatology, Use of Gene Expressing Profiling in Melanoma Prognosis
April 27, 2021@ 3 p.m. E.T.: Steven Trocha, M.D., surgical oncologist, Lifetime Clinic for High-Risk Melanoma Patients
“Disease awareness, preventive methods and early detection are all key factors that contribute to the best patient outcomes,” said
“Our mission is to prevent melanoma in as many people as possible,” said
For more information on the “Ask the Expert” Facebook Live webinars, or to access a recorded playback of the sessions, please visit the MRF Facebook page here.
DecisionDx®-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 5,700 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risk of recurrence studies including more than 1,600 patients. To predict likelihood of sentinel lymph node positivity, the Company utilizes its proprietary algorithm, i31-GEP, to produce an integrated test result. i31-GEP is an artificial intelligence-based neural network algorithm (independently validated in a cohort of 1,674 prospective, consecutively tested patients with T1-T4 cutaneous melanoma) that integrates the DecisionDx-Melanoma test result with the patient’s traditional clinicopathologic features. Impact on patient management plans for one of every two patients tested has been demonstrated in four multicenter and single-center studies including more than 560 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results. Through
More information about the test and disease can be found at www.CastleTestInfo.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of
Investor and Media Contact: